Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2016—The AIA-900 Benchtop model is now available from Tosoh. The AIA-900 uses Tosoh’s Unit Dose Test Cup reagent technology. Single, unitized test cups do not require premixing, premeasuring, or onboard refrigeration. The AIA-Pack test cup format works with every Tosoh AIA automated immunoassay system. Reagents are interchangeable, so laboratories with more than one Tosoh system can use the same reagents.
June 2016—SeraCare Life Sciences launched an expanded product line to support NGS-based somatic tumor profiling assay development, validation, and QC performance monitoring. The eight new Seraseq Solid Tumor Mutation Mix-II products contain 40 somatic variants with increases in the number of insertion-deletion mutations from four to 13 to challenge both the sequencing and variant calling algorithms.
June 2016—On May 4 Siemens Healthcare unveiled its new name, Siemens Healthineers. According to a company statement, the name “embodies the company’s pioneering spirit and engineering expertise in the healthcare industry.”
June 2016—Thermo Fisher Scientific received 510(k) clearance for two new EliA IgG tests for detecting anti-thyroglobulin and anti-thyroid peroxidase autoantibodies in serum or plasma. The CLIA-moderate laboratory tests are performed on the fully automated Phadia 250, 2500, and 5000 laboratory systems.
May 2016—Bio SB is offering 50 new antibodies for in vitro diagnostic applications. This generation of antibodies offers higher affinity, sensitivity, and specificity when compared with the previous generation of mouse monoclonal and polyclonal antibodies traditionally used in diagnostic immunohistochemistry applications. “Our new RBT and EP clones of rabbit monoclonal antibodies are unique reagents for cancer research and diagnostics,” Alfonso Heras, DVM, PhD, president and CEO of Bio SB, said in a statement. Among them are BRAF V600E, B7/H3,
May 2016—Luminex received medical device licenses from Health Canada’s Therapeutic Products Directorate, Medical Devices Bureau, for the Aries System and Aries HSV 1&2 Assay; both were FDA cleared in October 2015 and were subsequently launched in the U.S. market.
May 2016—MR Solutions’ 3-D in vivo confocal microscope for use in preclinical research provides a magnification range of up to 1,000 times, allowing researchers to examine cellular details within a live small animal, eliminating the need for a surgical biopsy.
May 2016—Horizon Discovery Group introduced its microinjection-ready Cas9 Accelerate Ribonucleoprotein. Cas9 Accelerate RNP maximizes gene-editing efficiency by enabling CRISPR …
May 2016—Sysmex America has signed a nonexclusive distributor agreement with Medline Industries, a manufacturer and distributor of health care supplies.
ay 2016—GenomeDx Biosciences launched Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis, and cancer-specific death at the time of biopsy in men with prostate cancer.
